Recombinant Human Podoplanin protein (rFc Tag)(HPLC verified)

种属

Human

纯度

>90 %, SDS-PAGE
>90 %, SEC-HPLC

标签

rFc Tag

生物活性

未测试

Cat no : Eg5024

Print datasheet

Synonyms

PDPN, 29kDa cytosolic podoplanin intracellular domain, Aggrus, PA2.26 antigen, PSEC0003



产品信息

纯度 >90 %, SDS-PAGE
>90 %, SEC-HPLC
内毒素 <0.1 EU/μg protein, LAL method
生物活性
Not tested
来源 HEK293-derived Human Podoplanin protein Ala23-Leu131 (Accession# Q86YL7-1) with a rabbit IgG Fc tag at the C-terminus.
基因ID 10630
蛋白编号 Q86YL7-1
预测分子量 37.4 kDa
SDS-PAGE 48-68 kDa, reducing (R) conditions
组分 Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
复溶 Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
储存条件
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
运输条件 The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

背景信息

Podoplanin (PDPN) is a transmembrane glycoprotein that plays a role in a variety of biological processes including regulation of blood-lymphatic vessel development, cerebral vascular pattern and integrity, cell motility, tumorigenesis and metastasis, and mediates tumor cell-induced platelet aggregation in different cancer types. It is a lymphatic marker because the expression of podoplanin has been detected in lymphatic but not blood vascular endothelium, and is useful as the marker of tumor-associated Lymphangiogenesis. When expressed in keratinocytes, PDPN induces changes in cell morphology with transfected cells showing an elongated shape, numerous membrane protrusions, major reorganization of the actin cytoskeleton, increased motility and decreased cell adhesion.

参考文献:

1. Ukaji T, et al . Cancer Sci. 2021; 112(6):2299-2313. 2. Krishnan H, et al. J Biol Chem. 2013 ;288(17):12215-21. 3. Wang X, et al. Cancer Gene Ther. 2023 ;30(2):345-357. 4.Astarita JL, et al. Front Immunol. 2012; 3:283.